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logic response. However, H-Y serologic response is strongly asso-
ciated with cGVHD in a multivariable logistic model (p  0.007).
These results support the hypothesis that B cell responses to H-Y
mHA play an important role in the pathogenesis of cGVHD and
suggests that anti-B cell therapy may be useful in the treatment of
this disease.
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CHARACTERIZATION OF THE TUMOR-SPECIFIC ACTIVITY OF WT1 SPE-
CIFIC T CELLS GENERATED IN VITRO FROM NORMAL INDIVIDUALS BY
SENSITIZATION WITH WT1-PEPTIDE LOADED AUTOLOGOUS EBV
TRANSFORMED B CELLS
Doubrovina, E.S., Doubrovin, M.M., Shieh, J.H., Bierwiaczonek, A.,
Heller, G., Pamer, E., O’Reilly, R.J. Memorial Sloan-Kettering Cancer
Center, New York, NY
The Wilms’ tumor protein WT1 is over-expressed in most acute
and chronic leukemias. Isolated T-cell clones have been reported
to recognize WT1 peptides binding by HLA-A0201 and HLA-
A2402 and lyse WT1 leukemic lines. To test WT1 peptide
immunogenicity in normal individuals, we sensitized T-cells from
9 HLA-A0201 and 4 HLA-A2402 donors with autologous EBV
transformed B cells (EBV-BLCL) or cytokine-activated monocytes
(CAM), loaded with HLA-A0201-binding WT1 peptides RMFP-
NAPYL or SLGEQQYSV or the HLA- A2402- binding WT1
peptide RVPGVAPTL. WT1-peptide speciﬁc cytotoxic and inter-
feron-gamma producing T-cells were generated from each donor.
T-cells sensitized with peptide-loaded EBV-BLCL generated
higher numbers of WT1 speciﬁc T-cells than peptide loaded
CAM. The frequencies of WT1 peptide-speciﬁc T-cells measured
by binding to peptide-HLA tetramers were similar to those gen-
erated against individual immunogenic HLA-A0201 binding EBV
peptides. These T-cells speciﬁcally lysed WT1 leukemias (n 
16) and solid tumors (n  12) in an HLA-restricted manner, but
neither lysed autologous or HLA-sharing normal CD34 hema-
topoietic progenitor cells (n  12) nor affected their yield of
CFU-GM, BFU-C or CFU-MIX. Following adoptive transfer into
SCID mice bearing subcutaneous xenografts of WT1 and WT1-,
HLA-A0201 leukemias, WT1-peptide-speciﬁc T-cells preferen-
tially accumulated in and induce regressions only of WT1 leu-
kemias . The long-term repeated in vivo scintigraphic imaging of
such T cells, transduced to express an HSV-TK/GFP fusion gene,
following intravenous infusions of the HSV-TK substrate [131I]-
FIAU demonstrated progressive accumulation of the T cells over a
period of 8 days in tumors, expressing targeted antigen and the
HLA restricting allele. These studies demonstrate that T cells
speciﬁc to the self antigen WT1 can be regularly generated from
normal individuals and that these cells exhibit signiﬁcant anti-
tumor activity both in vitro and in vivo. Such cells may prove useful
for adoptive therapy of leukemias in man.
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EX VIVO ACTIVATED AND EXPANDED CD8 T CELLS RECOGNIZE
MALIGNANT CELLS THROUGH A TCR INDEPENDENT AND NKG2D DE-
PENDENT PATHWAY
Verneris, M.R.1, Karami, M.2, Baker, J.2, Jasawal, A.1, Negrin, R.S.2
1. University of Minnesota, Minneapolis, MN; 2. Stanford University,
Stanford, CA
T cells that are activated by TCR crosslinking antibodies and
expanded with high doses of IL-2 attain cytotoxicity against ma-
lignant target cells without prior exposure or antigen priming. The
mechanism of this MHC-unrestricted cytotoxicity is unknown.
NKG2D is a cell surface receptor on both NK and CD8 T cells.
Here we examined ex vivo activated and expanded CD8 T cells to
determine if NKG2D plays a role in the recognition and triggering
of cytotoxicity against malignant targets. FACS analysis showed
that NKG2D could be detected on freshly isolated CD8 cells and
expression is increased after 21 days of culture. To access the
functional role of NKG2D on ex vivo activated and expanded
CD8 T cells we performed 51Cr release assays using NKG2D
blocking antibodies. Blocking NKG2D attenuated the killing of
malignant cell targets by 75%, while control antibodies had no
effect. Similarly, blocking NKG2D counter-ligands on malignant
targets attenuated cytotoxicity by 50-100%. To conﬁrm and ex-
tend these ﬁndings, we designed siRNA against NKG2D. 72 hours
after siRNA transfection, surface NKG2D was nearly undetect-
able, while other proteins (TCR or CD3) were unchanged. Cells
treated with NKG2D siRNA were not cytotoxic, while those
treated with control siRNA had cytotoxicity similar to non-trans-
fected cells. To determine whether NKG2D ligation alone trig-
gered cytotoxicity, we performed redirected killing assays using Fc
bearing murine target cells. Cells loaded with NKG2D antibodies,
but not isotype control antibodies, triggered cytotoxicity. To fur-
ther demonstrate NKG2D dependent, TCR independent target
recognition, we used FACS puriﬁed activated and expanded CD8
T cells and MHC class I def. targets which can not present peptide
antigen to CD8 T cells. Activated and expanded CD8 T cells
lysed these targets and blocking NKG2D nearly completely inhib-
ited cytolysis. Activated and expanded T cells acquire cytolytic
activity at day 10 of culture, in response to high (300 U/ml), but
not low (30 U/ml) concentrations of IL-2. DAP10 is the only
known adapter protein to transmit NKG2D signals in humans. We
therefore assayed for DAP10 at various time points in culture.
DAP10 was not detected until day 10, and only in response to high
doses of IL-2. Collectively, these studies show that activated and
expanded CD8 T cells recognize targets through a NKG2D
dependent, TCR independent pathway, likely controlled at the
level of DAP10 expression in response to IL-2.
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MODULATION OF TREG CELLS BY EXTRACORPOREAL PHOTOPHERESIS
IN CHRONIC GRAFT-VS-HOST DISEASE
Xie, M., Chan, G., Foss, F. Tufts New England Medical Center, Boston,
MA
While the pathogenesis of chronic graft-vs-host disease has not
been fully elucidated, alloreactive T cells, antigen presenting cells
(APC) and inﬂammatory cytokine secretion have been implicated.
Extracorporeal photopheresis (ECP) has demonstrated efﬁcacy in
patients with steroid-refractory acute and chronic GVHD. While
the mechanism of action of ECP in GVHD remains to be fully
deﬁned, we have demonstrated that clinical response in patients
with extensive, refractory cGVHD was associated with normaliza-
tion of skewed CD4/CD8 ratios and alterations in dendritic cell
and T-cell phenotypes, favoring a DC2/Th2 cytokine proﬁle.
These results suggest that ECP may indirectly or directly modulate
the function or activation of alloreactive T cells in GVHD. In an
attempt to determine the effects of ECP on T cell activation we
have examined the expression of negative co-stimulatory molecules
on T cells from cGVHD patients treated with ECP. We found
signiﬁcant changes in ICOS (inducible costimulatory molecule),
but not PD-l (programmed death gene 1) and CD137 (4-1BB) on
T cells during ECP treatment. Of 16 patients studied, we found
that clinical response to ECP was associated with an increase of
CD4ICOS cells. ICOS T-cells are a strong stimulator of
IL-10 production and Th2 differentiation, and we have previously
reported that ECP treatment is associated with an increase in
IL-10 production by T-helper cells in patients with cGVHD.
Populations of CD4CD25 cells have recently been identiﬁed as
immunoregulatory T cells (Treg), however a recent study of allo-
geneic stem cell grafts suggests that CD4/CD25 coexpression may
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